Original Article
Brief Report
Deficiency of Cartilage-Associated Protein in Recessive Lethal Osteogenesis Imperfecta
N Engl J Med 2006; 355:2757-2764December 28, 2006
- Abstract
Classic osteogenesis imperfecta, an autosomal dominant disorder associated with osteoporosis and bone fragility, is caused by mutations in the genes for type I collagen. A recessive form of the disorder has long been suspected. Since the loss of cartilage-associated protein (CRTAP), which is required for post-translational prolyl 3-hydroxylation of collagen, causes severe osteoporosis in mice, we investigated whether CRTAP deficiency is associated with recessive osteogenesis imperfecta. Three of 10 children with lethal or severe osteogenesis imperfecta, who did not have a primary collagen defect yet had excess post-translational modification of collagen, were found to have a recessive condition resulting in CRTAP deficiency, suggesting that prolyl 3-hydroxylation of type I collagen is important for bone formation.
Media in This Article
Figure 1
Clinical Characteristics of Infants with CRTAP Deficiency.Figure 2
Results of Analyses of CRTAP mRNA and Biochemical Analyses of CRTAP and Type I Collagen.Article Activity
- Article
Osteogenesis imperfecta, or “brittle bone disease,” is an autosomal dominant genetic disorder characterized by bone fragility with susceptibility to fracture.1 The clinical range of osteogenesis imperfecta (types I through IV)2 extends from mild symptoms to a perinatal lethal condition (Table 1 of the Supplementary Appendix, available with the full text of this article at www.nejm.org). Mutations in type I collagen, the major structural protein of bone and skin, cause most cases of osteogenesis imperfecta.3
Type I collagen is a heterotrimer, composed of two α1(I) and one α2(I) chains. Both α chains have a primary structure of uninterrupted repeats of the tripeptide composed of glycine (Gly) and two other amino acids, often proline (Pro) and hydroxyproline (Hyp), in that order. This primary structure allows the procollagen chains to form a triple helix, with the chains aligning at their carboxyl ends and folding toward the amino termini.4 Heterozygous mutations affecting the primary collagen structure cause moderate and severe osteogenesis imperfecta, whereas decreased collagen production causes mild osteogenesis imperfecta.3 A recessive form of osteogenesis imperfecta has long been suspected in some cases, in which unaffected parents have more than one child with severe bone dysplasia.5-8 Proposals of additional dominant and recessive types of osteogenesis imperfecta (types V through VII) are based on histologic characteristics of bone; these nonlethal forms do not involve primary collagen defects.9-11
Type I procollagen undergoes intracellular post-translational modifications.12 Specific proline and lysine residues throughout the helical region of the collagen chains are hydroxylated to 4-hydroxyproline, 3-hydroxyproline, and hydroxylysine by prolyl 4-hydroxylase, prolyl 3-hydroxylase 1, and lysyl hydroxylase, respectively, with subsequent glycosylation of some hydroxylysine residues.13 4-Hydroxyproline residues are crucial for collagen folding and stability.
Prolyl 3-hydroxylase 1, located in the endoplasmic reticulum, modifies Pro-4Hyp-Gly,14,15 specifically the proline residue in the 986 position (Pro986) in the α1(I) chain.15,16 Prolyl 3-hydroxylase 1 forms a complex with cartilage-associated protein (CRTAP) and cyclophilin B, although CRTAP is not required for prolyl 3-hydroxylase 1 activity in vitro.17,18 CRTAP messenger RNA (mRNA) is detectable in many types of cells, including osteoblasts,18-21 and is secreted into the extracellular matrix of cartilage and long bones.19 In Crtap-null mice, kyphosis and severe osteoporosis develop, with defective osteoid formation18; the α1(I) chains completely lack Pro986 hydroxylation. We screened skin samples from 10 children with lethal or severe osteogenesis imperfecta who had type I collagen with a normal primary structure and identified mutations in the CRTAP gene in infants with decreased levels of CRTAP mRNA.
Methods
Study Population
We screened dermal fibroblasts from 10 children with lethal (type II) or very severe (type III) osteogenesis imperfecta who had type I collagen with a normal primary structure but with excess post-translational modification of the α chain helical region. A well-studied fibroblast cell line from newborn foreskin (American Type Culture Collection 2127) was used as a control. We also examined 1 control patient with classic (type III) osteogenesis imperfecta, 6 normal control subjects, and 11 patients who had severe osteogenesis imperfecta without excess modification and without a collagen defect; none had decreased hydroxylation of Pro986 (data not shown). Written informed consent was obtained from all patients and control subjects or their parents.
Detection of CRTAP Mutations, mRNA Levels, and Splicing Isoforms
The 7 CRTAP exons and surrounding intronic sequences were amplified from the subjects' genomic DNA with the use of a polymerase-chain-reaction (PCR) assay and were sequenced on a Beckman CEQ2000 assay sequencer. CRTAP mRNA levels in affected infants, their parents, and control fibroblasts were determined with the use of real-time reverse-transcriptase (RT) PCR (Assays-on-Demand, Applied Biosystems). To determine the splicing isoforms of Infant 1, total RNA from cycloheximide-treated fibroblasts was amplified by RT-PCR. Amplified products were subcloned and sequenced.
In Vitro Biochemical Analyses
For Western blots of CRTAP protein, total fibroblast lysates were separated by means of sodium dodecyl sulfate–polyacrylamide-gel electrophoresis (SDS-PAGE) and were electroblotted.18 The blots were probed with CRTAP polyclonal antibody. Reactive bands were visualized with the use of a secondary antibody, conjugated with horseradish peroxidase, and chemiluminescence (Pierce Biotechnology). The loading control was γ tubulin. To assess the degree of collagen modification, steady-state procollagen was digested with pepsin and electrophoresed, under nonreducing conditions, with the use of SDS-urea-PAGE. Differential scanning calorimetry and amino acid chromatography were performed according to standard methods. For evaluation of prolyl 3-hydroxylation, electrospray mass spectrometry was performed on tryptic peptides of the α1(I) chains (for details, see the Supplementary Appendix).
Results
Clinical Findings of CRTAP Deficiency
Infant 1, the first child of a couple of Pakistani origin who are full second cousins, was a boy weighing 2370 g who was born at 35 weeks' gestation after an induced vaginal delivery. Prenatal ultrasonography revealed severe micromelia of the arms and legs. The birth length was 43 cm and the head circumference was 29.5 cm — values at the 50th percentile for an infant at 32 weeks gestation. There was a wide-open anterior fontanel. The eyes showed proptosis and white sclerae. He had pectus excavatum and rhizomelic limb shortening, and held his legs in an externally rotated and abducted position. A radiographic survey revealed over 20 fractures of the long bones and ribs (Figure 1A through 1DFigure 1
Clinical Characteristics of Infants with CRTAP Deficiency.). Ultrasonography revealed moderate hydronephrosis on the left side and a small right kidney. He required 10 days of mechanical ventilation and was discharged at 1 month, receiving nasal oxygen. At 6 months of age, his weight, length, and head circumferences were at the 50th percentile for newborn boys and 1- and 4-month-old boys, respectively. He died at 10 months of age during hospitalization for respiratory syncytial virus bronchiolitis.Infant 2 was a girl weighing 2435 g who was born at 36 weeks' gestation to nonconsanguineous black parents after a spontaneous vaginal delivery. The infant's parents and two half-siblings were healthy. The birth length was 38 cm (50th percentile for infants at 29 weeks' gestation). The head circumference was 31.7 cm (50th percentile for infants at 33.5 weeks' gestation); the skull was soft, and the anterior fontanel and the other sutures were wide open. The eyes showed proptosis, and the sclerae were white. The limbs were deformed, and the skeletal survey revealed fractures of the femurs, tibiae, humeri, and multiple ribs (Figure 1E). The infant's chest was small, and she required ventilation for respiratory distress. Cardiac catheterization on day 18 revealed an absent right pulmonary artery with a collateral vessel from the proximal descending aorta supplying the trilobed right lung, hypoplastic pulmonary veins, and systemic pulmonary hypertension. The aorta was normal. Echocardiography on day 75 showed right ventricular hypertrophy and dilatation. She died on day 80 from respiratory insufficiency.
Infant 3 was a girl weighing 2600 g (50th percentile for infants at 36 weeks' gestation) delivered by elective cesarean section at term to nonconsanguineous parents of German descent. The couple had had four children previously, including one with severe skeletal dysplasia who died from pneumonia at 5 months of age. Infant 3 did not require respiratory support at birth. The skull was poorly ossified, and the anterior and posterior fontanels were wide open. The sclerae were light blue. There was micromelia of the arms and legs, and the legs were held in an abducted position. Skeletal surveys showed crumpling of both femurs, multiple rib fractures, and wormian bones of the skull (Figure 1F). The infant's cardiorespiratory status allowed her to gain weight as a result of breast-feeding. At 2 months of age, her weight was that of an average newborn, her length was 45 cm, and her head circumference was 36 cm (50th percentile for 34 weeks' gestation and 5th percentile for age, respectively). There was a pectus excavatum (Figure 1G). Findings on cardiac and pulmonary examinations were normal. The spine was straight. She had begun to smile and coo. She died at 10 months from respiratory insufficiency and pneumonia.
Expression of CRTAP in Fibroblasts from Infants and Parents
We sampled mRNA from the fibroblasts of the 10 children with lethal or severe osteogenesis imperfecta with excess post-translational modification but without a collagen mutation and screened it for decreased levels of CRTAP mRNA. Infants 1, 2, and 3 had CRTAP mRNA levels that were 0 to 25% of the normal value (Figure 2AFigure 2
Results of Analyses of CRTAP mRNA and Biochemical Analyses of CRTAP and Type I Collagen.). Fibroblasts from the parents of Infants 1 and 3 had normal CRTAP mRNA levels, suggesting that the infants had more than one defective allele.Identification of CRTAP Mutations
We sequenced the exons and surrounding intronic sequences of CRTAP from Infants 1, 2, and 3, who had reduced levels of CRTAP expression. Mutations were identified in all three infants (see Figure 1 in the Supplementary Appendix). Infant 1 was homozygous for a mutation in the splice donor site of exon 1 at the invariant first intronic nucleotide (IVS1+1G→C). Both parents were heterozygous for this mutation (see Figure 1A1 in the Supplementary Appendix). Infant 2 was homozygous for a point mutation that directly causes a Gln276→Stop substitution in exon 4, which results in the termination of translation at amino acid 275 of 401 CRTAP residues (see Figure 1B in the Supplementary Appendix). Infant 3 was a compound heterozygote. From her father, she had inherited a point mutation in the CRTAP start codon (AUG→AUA), causing a Met1→Ile substitution, which is expected to eliminate the initiation of CRTAP translation (see Figure 1C1 in the Supplementary Appendix). From her mother, she had inherited a 16-nucleotide duplication in exon 1, which shifts the reading frame and results in a premature termination codon in exon 2 (see Figure 1C2 in the Supplementary Appendix). The presence of the parental mutations was confirmed by restriction-enzyme digestion.
The splice donor site mutation in Infant 1 results in four alternatively spliced forms of the mRNA transcript (see Figure 1A2 in the Supplementary Appendix), each containing a premature termination codon in the retained portion of intron 1, a finding that is consistent with rapid degradation of the abnormal mRNA and undetectability of the splicing isoforms with the use of an RNA protection assay; the normally spliced mRNA in the parents and the control cell line was detectable (data not shown).
CRTAP Deficiency in Fibroblasts
Intracellular CRTAP was detectable in fibroblasts from the control cell line and from the parents but was undetectable in fibroblasts from Infants 1, 2, and 3 (Figure 2B), as measured by Western blot. The father of Infant 3, whose mutation alters the start codon, produced both normal CRTAP and CRTAP of smaller size, suggesting that his cells contain a truncated form of CRTAP. Without the normal start codon, protein synthesis may be initiated at the next methionine codon, Met42. We did not detect the truncated form in several independent samples from Infant 3; stabilization of the truncated protein may require the presence of normal CRTAP.
Effect of CRTAP Deficiency on Type I Collagen
Tandem mass spectrometry revealed a lack or reduction of prolyl 3-hydroxylation at Pro986 (Figure 2A in the Supplementary Appendix) in the α1(I) chain in the infants; Infant 3 had 3-hydroxylation of 21% of α1(I)Pro986 residues, suggesting that she had residual enzyme activity from her paternal allele (Figure 2C and Table 1Table 1
Hydroxylation of Type I Collagen.). The lack of prolyl 3-hydroxylation, CRTAP function, or both delayed the folding of the collagen helix and allowed for excess modification by lysyl hydroxylase and prolyl 4-hydroxylase along the full length of the helix. Collagen chains from Infants 1, 2, and 3 showed delayed electrophoretic migration on SDS-urea-PAGE (Figure 2D through 2F), with a 28 to 43% increase in the hydroxylation of lysine residues as compared with normal collagen (Table 1). These findings resemble those from collagen with a structural mutation in the carboxyl end of the helical region, and they are consistent with the increase in the melting temperature of collagen of approximately 1°C on calorimetry (Figure 2B in the Supplementary Appendix).Discussion
We identified 10 children who had lethal or severe osteogenesis imperfecta without primary collagen mutations but with excess post-translational modification of type I collagen, indicative of delayed folding of the collagen helix. Most patients with osteogenesis imperfecta and overmodified collagen have a structural mutation in one of the two chains of type I collagen. However, in 10 to 15% of cases of osteogenesis imperfecta, no collagen mutation is found, suggesting that alterations are present in other genes.
In 3 of the 10 children, we identified a recessive form of lethal osteogenesis imperfecta, caused by null mutations in CRTAP, a gene that encodes a protein that is essential for one of the post-translational modifications of types I and II collagen.18 The affected infants had defects in both CRTAP alleles, low levels of CRTAP mRNA, a lack of CRTAP protein, and minimal prolyl 3-hydroxylation of type I collagen. The CRTAP mutations led to premature termination of translation, triggering intracellular destruction of the mutant mRNA transcripts. The parents of Infants 1 and 3, who were available for mutation analysis, were heterozygous carriers; they had minimally reduced levels of CRTAP mRNA, CRTAP protein, and Pro986 hydroxylation in the α1(I) chain. The parents of Infant 2 did not participate in the analysis, but the infant had a homozygous point mutation that directly causes a Gln276→Stop substitution in exon 4 of CRTAP. CRTAP mutations did not account for our other seven cases of severe osteogenesis imperfecta without a primary collagen defect. It is also difficult to know what proportion of all cases of lethal osteogenesis imperfecta is caused by CRTAP mutations, because the genes for type I collagen (COL1A1 and COL1A2) are not sequenced in many cases for which there is a positive biochemical test. A reasonable preliminary estimation is that CRTAP defects cause 2 to 3% of cases of lethal osteogenesis imperfecta.
Although infants with CRTAP deficiency have a clinical presentation similar to that of infants with perinatal lethal type II osteogenesis imperfecta,2 there are distinctive features. In patients with CRTAP deficiency owing to a recessive mutation, head circumference is relatively small, the eyes show proptosis because of shallow orbits, and the sclerae are white or light blue; patients with type II osteogenesis imperfecta and a structural collagen defect have relative macrocephaly and dark blue sclerae. In recessive and dominant lethal osteogenesis imperfecta, the bones are severely undermineralized, have multiple fractures prenatally, and result in an abducted positioning of the legs. On radiography, the long bones in infants with CRTAP deficiency are characterized by a lack of diaphyseal modeling (undertubulation). In both the dominant and recessive forms, respiratory insufficiency causes early death.
Both recessive and dominant lethal osteogenesis imperfecta result in increased modification of the type I collagen helix. Classic dominantly inherited osteogenesis imperfecta involves defects in the primary sequence of the collagen chains22 that delay triple helix formation at the site of the defect,23 exposing the constituent chains to increased collagen modification by lysyl and prolyl hydroxylases at multiple sites along the length of the helix12,13 and causing delayed electrophoretic migration of collagen chains.24 Recessive CRTAP deficiency results in no or minimal Pro986 hydroxylation near the carboxyl end of collagen, where triple helix formation begins.4 CRTAP function, 3-hydroxylation, or both must be crucial for triple helix folding, since the lack of these processes also results in excess modification of the helical regions of the chains and the same delayed electrophoretic migration as seen in dominant osteogenesis imperfecta.
Our study shows that CRTAP acts as part of a collagen 3-hydroxylation complex17 and may also directly mediate collagen helical assembly. The human CRTAP gene has been mapped to chromosome 3p22,21 as has been type VII osteogenesis imperfecta, a recessive, severe, nonlethal form of osteogenesis imperfecta with distinctive histologic characteristics of the bone.11,25 A partially functional CRTAP mutant allele was recently identified in patients with type VII osteogenesis imperfecta.18 In contrast, the infants described here had null CRTAP mutations, excess modification of type I collagen, and a condition that was lethal in the first year of life. The spectrum of murine Crtap and human CRTAP mutations suggests that prolyl 3-hydroxylation of type I collagen is crucial for normal bone formation. A lack of prolyl 3-hydroxylation in other collagen types may affect the development of multiple organs (including the heart, kidney, and lung), which may contribute to the lethal outcome.
Supported by intramural funding from the National Institute of Child Health and Human Development (to Drs. Marini and Leikin) and by grants from the National Institutes of Health (DE016990 to Dr. Lee, HD22657 to Drs. Lee and Eyre, and AR37318 to Dr. Eyre) and the Kimberly V. Talley Chair of Genetics at the University of Oklahoma Health Sciences Center (to Dr. Mulvihill).
No potential conflict of interest relevant to this article was reported.
Ms. Barnes and Drs. Chang and Morello contributed equally to this article.
We thank the parents of the affected infants for their support, especially the family of Infant 3 for their dedication through years of various investigations; the nurses of the former 9 West Pediatric Unit, National Institutes of Health Clinical Center, for their care of Infants 1 and 3; Melissa A. Scott for her skillful assistance in the preparation of collagen for mass spectrometry analysis; and Anna Galicka, Ph.D., for the sequencing of collagen complementary DNA.
Source Information
From the National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD (A.M.B., W.C., W.A.C., S.L., E.M., N.K., T.E.U., A.A., A.W.F., J.C.M.); Baylor College of Medicine, Houston (R.M., B.L.); the Orthopaedic Research Laboratories, University of Washington, Seattle (M.W., D.R.E.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.J.M., P.L.W.); and the Medical College of Virginia, Richmond (U.T.S.).
Address reprint requests to Dr. Marini at the Bone and Extracellular Matrix Branch, NICHD, NIH, Bldg. 10, Rm. 10N260, 9000 Rockville Pike, Bethesda, MD 20892, or at oidoc@helix.nih.gov.
- References
References
1
Marini JC. Osteogenesis imperfecta. In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson textbook of pediatrics. 17th ed. Philadelphia: W.B. Saunders, 2004:2336-8.
2
Sillence DO ,Senn A ,Danks DM . Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979;16:101-116
CrossRef | Web of Science | Medline3
Byers P, Cole W. Osteogenesis imperfecta. In: Royce PM, Steinmann B, eds. Connective tissue and its heritable disorders: molecular, genetic, and medical aspects. 2nd ed. New York: Wiley-Liss, 2002:385-430.
4
Bruckner P ,Eikenberry EF . Formation of the triple helix of type I procollagen in cellulo: temperature-dependent kinetics support a model based on cis in equilibrium trans isomerization of peptide bonds. Eur J Biochem 1984;140:391-395
CrossRef | Medline5
Aitchison K ,Ogilvie D ,Honeyman M ,Thompson E ,Sykes B . Homozygous osteogenesis imperfecta unlinked to collagen I genes. Hum Genet 1988;78:233-236
CrossRef | Web of Science | Medline6
Byers PH ,Tsipouras P ,Bonadio JF ,Starman BJ ,Schwartz RC . Perinatal lethal osteogenesis imperfecta (OI type II): a biochemically heterogeneous disorder usually due to new mutations in the genes for type I collagen. Am J Hum Genet 1988;42:237-248
Web of Science | Medline7
Wallis GA ,Sykes B ,Byers PH ,Mathew CG ,Viljoen D ,Beighton P . Osteogenesis imperfecta type III: mutations in the type I collagen structural genes, COL1A1 and COL1A2, are not necessarily responsible. J Med Genet 1993;30:492-496
CrossRef | Web of Science | Medline8
Williams EM ,Nicholls AC ,Daw SC , et al. Phenotypical features of an unique Irish family with severe autosomal recessive osteogenesis imperfecta. Clin Genet 1989;35:181-190
CrossRef | Web of Science | Medline9
Glorieux FH ,Rauch F ,Plotkin H , et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res 2000;15:1650-1658
CrossRef | Web of Science | Medline10
Glorieux FH ,Ward LM ,Rauch F ,Lalic L ,Roughley PJ ,Travers R . Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 2002;17:30-38
CrossRef | Web of Science | Medline11
Ward LM ,Rauch F ,Travers R , et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 2002;31:12-18
CrossRef | Web of Science | Medline12
Kielty C, Grant M. The collagen family: structure, assembly, and organization in the extracellular matrix. In: Royce PM, Steinmann B, eds. Connective tissue and its heritable disorders: molecular, genetic, and medical aspects. 2nd ed. New York: Wiley-Liss, 2002:159-221.
13
Kivirikko K, Myllyla R. The hydroxylation of prolyl and lysyl residues. In: Freedman RB, Hawkins HC, eds. The enzymology of post-translational modification of proteins. London: Academic Press, 1980:53-104.
14
Risteli J ,Tryggvason K ,Kivirikko KI . Prolyl 3-hydroxylase: partial characterization of the enzyme from rat kidney cortex. Eur J Biochem 1977;73:485-492
CrossRef | Medline15
Fietzek PP ,Rexrodt FW ,Wendt P ,Stark M ,Kuhn K . The covalent structure of collagen: amino-acid sequence of peptide 1-CB6-C2. Eur J Biochem 1972;30:163-168
CrossRef | Medline16
Fietzek PP ,Kuhn K . The primary structure of collagen. Int Rev Connect Tissue Res 1976;7:1-60
Medline17
Vranka JA ,Sakai LY ,Bachinger HP . Prolyl 3-hydroxylase 1, enzyme characterization and identification of a novel family of enzymes. J Biol Chem 2004;279:23615-23621
CrossRef | Web of Science | Medline18
Morello R ,Bertin TK ,Chen Y , et al. CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell 2006;127:291-304
CrossRef | Web of Science | Medline19
Castagnola P ,Gennari M ,Morello R , et al. Cartilage associated protein (CASP) is a novel developmentally regulated chick embryo protein. J Cell Sci 1997;110:1351-1359
Web of Science | Medline20
Morello R ,Tonachini L ,Monticone M , et al. cDNA cloning, characterization and chromosome mapping of Crtap encoding the mouse cartilage associated protein. Matrix Biol 1999;18:319-324
CrossRef | Web of Science | Medline21
Tonachini L ,Morello R ,Monticone M , et al. cDNA cloning, characterization and chromosome mapping of the gene encoding human cartilage associated protein (CRTAP). Cytogenet Cell Genet 1999;87:191-194
CrossRef | Medline22
Marini JC, Forlino A, Cabral WA, et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat (in press).
23
Raghunath M ,Bruckner P ,Steinmann B . Delayed triple helix formation of mutant collagen from patients with osteogenesis imperfecta. J Mol Biol 1994;236:940-949
CrossRef | Web of Science | Medline24
Bonadio J ,Holbrook KA ,Gelinas RE ,Jacob J ,Byers PH . Altered triple helical structure of type I procollagen in lethal perinatal osteogenesis imperfecta. J Biol Chem 1985;260:1734-1742
Web of Science | Medline25
Labuda M ,Morissette J ,Ward LM , et al. Osteogenesis imperfecta type VII maps to the short arm of chromosome 3. Bone 2002;31:19-25
CrossRef | Web of Science | Medline
- Citing Articles (66)
Citing Articles
1
Mona S. Aglan, Laila Hosny, Rasha El-Houssini, Sawsan Abdelhadi, Fadia Salem, Rokia A. S. ElBanna, Seham A. Awad, Moushira E. Zaki, Samia A. Temtamy. (2012) A scoring system for the assessment of clinical severity in osteogenesis imperfecta. Journal of Children's Orthopaedics
CrossRef2
Wayne A. Cabral, Aileen M. Barnes, Adebowale Adeyemo, Kelly Cushing, David Chitayat, Forbes D. Porter, Susan R. Panny, Fizza Gulamali-Majid, Sarah A. Tishkoff, Timothy R. Rebbeck, Serigne M. Gueye, Joan E. Bailey-Wilson, Lawrence C. Brody, Charles N. Rotimi, Joan C. Marini. (2012) A founder mutation in LEPRE1 carried by 1.5% of West Africans and 0.4% of African Americans causes lethal recessive osteogenesis imperfecta. Genetics in Medicine
CrossRef3
David L. Rimoin, George E. Tiller. 2012. Skeletal Dysplasias and Connective Tissue Disorders. , 258-276.
CrossRef4
Francis H Glorieux, David Rowe. 2012. Osteogenesis Imperfecta. , 511-539.
CrossRef5
Mathieu S. Davis, Bethany L. Kovacic, Joan C. Marini, Albert J. Shih, Kenneth M. Kozloff. (2011) Increased susceptibility to microdamage in Brtl/+ mouse model for osteogenesis imperfecta. Bone
CrossRef6
I.M. Ben Amor, F. Rauch, K. Gruenwald, M. Weis, D.R. Eyre, P. Roughley, F.H. Glorieux, R. Morello. (2011) Severe osteogenesis imperfecta caused by a small in-frame deletion in CRTAP. American Journal of Medical Genetics Part A 155:11, 2865-2870
CrossRef7
M Valli, AM Barnes, A Gallanti, WA Cabral, S Viglio, MA Weis, E Makareeva, D Eyre, S Leikin, F Antoniazzi, JC Marini, M Mottes. (2011) Deficiency of CRTAP in non-lethal recessive osteogenesis imperfecta reduces collagen deposition into matrix. Clinical Geneticsno-no
CrossRef8
Giacomo Venturi, Elena Monti, Luca Dalle Carbonare, Massimiliano Corradi, Alberto Gandini, Maria Teresa Valenti, Attilio Boner, Franco Antoniazzi. (2011) A novel splicing mutation in FKBP10 causing osteogenesis imperfecta with a possible mineralization defect. Bone
CrossRef9
Shikma Mordechai, Libe Gradstein, Annika Pasanen, Rivka Ofir, Khalil El Amour, Jaime Levy, Nadav Belfair, Tova Lifshitz, Sara Joshua, Ginat Narkis, Khalil Elbedour, Johanna Myllyharju, Ohad S. Birk. (2011) High Myopia Caused by a Mutation in LEPREL1, Encoding Prolyl 3-Hydroxylase 2. The American Journal of Human Genetics 89:3, 438-445
CrossRef10
Taichi Kitaoka, Noriyuki Namba, Kohji Miura, Takuo Kubota, Yasuhisa Ohata, Makoto Fujiwara, Haruhiko Hirai, Takehisa Yamamoto, Keiichi Ozono. (2011) Decrease in serum FGF23 levels after intravenous infusion of pamidronate in patients with osteogenesis imperfecta. Journal of Bone and Mineral Metabolism 29:5, 598-605
CrossRef11
Fleur S van Dijk, Peter H Byers, Raymond Dalgleish, Fransiska Malfait, Alessandra Maugeri, Marianne Rohrbach, Sofie Symoens, Erik A Sistermans, Gerard Pals. (2011) EMQN best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta. European Journal of Human Genetics
CrossRef12
Antonella Forlino, Wayne A. Cabral, Aileen M. Barnes, Joan C. Marini. (2011) New perspectives on osteogenesis imperfecta. Nature Reviews Endocrinology 7:9, 540-557
CrossRef13
Zhen-Lin Zhang, Hao Zhang, Yao-hua Ke, Hua Yue, Wen-Jin Xiao, Jin-Bo Yu, Jie-Mei Gu, Wei-Wei Hu, Chun Wang, Jin-Wei He, Wen-Zhen Fu. (2011) The identification of novel mutations in COL1A1, COL1A2, and LEPRE1 genes in Chinese patients with osteogenesis imperfecta. Journal of Bone and Mineral Metabolism
CrossRef14
Marc Lacour. 2011. Buschke-Ollendorff Syndrome, Marfan Syndrome, Osteogenesis Imperfecta, Anetodermas and Atrophodermas. , 145.1-145.21.
CrossRef15
Ranad Shaheen, Mohammed Al-Owain, Eissa Faqeih, Nadia Al-Hashmi, Ali Awaji, Zayed Al-Zayed, Fowzan S Alkuraya. (2011) Mutations in FKBP10 cause both Bruck syndrome and isolated osteogenesis imperfecta in humans. American Journal of Medical Genetics Part A 155:6, 1448-1452
CrossRef16
A M Courtwright, M M Laughon, M W Doron. (2011) Length of life and treatment intensity in infants diagnosed prenatally or postnatally with congenital anomalies considered to be lethal. Journal of Perinatology 31:6, 387-391
CrossRef17
Fleur S. van Dijk, Peter G. J. Nikkels, Nicolette S. den Hollander, Isabel M. Nesbitt, Rick R. van Rijn, Jan M. Cobben, Gerard Pals. (2011) Lethal/Severe Osteogenesis Imperfecta in a Large Family: A Novel Homozygous LEPRE1 Mutation and Bone Histological Findings. Pediatric and Developmental Pathology 14:3, 228-234
CrossRef18
S. M. Pyott, U. Schwarze, H. E. Christiansen, M. G. Pepin, D. F. Leistritz, R. Dineen, C. Harris, B. K. Burton, B. Angle, K. Kim, M. D. Sussman, M. Weis, D. R. Eyre, D. W. Russell, K. J. McCarthy, R. D. Steiner, P. H. Byers. (2011) Mutations in PPIB (cyclophilin B) delay type I procollagen chain association and result in perinatal lethal to moderate osteogenesis imperfecta phenotypes. Human Molecular Genetics 20:8, 1595-1609
CrossRef19
Jutta Becker, Oliver Semler, Christian Gilissen, Yun Li, Hanno Jörn Bolz, Cecilia Giunta, Carsten Bergmann, Marianne Rohrbach, Friederike Koerber, Katharina Zimmermann, Petra de Vries, Brunhilde Wirth, Eckhard Schoenau, Bernd Wollnik, Joris A. Veltman, Alexander Hoischen, Christian Netzer. (2011) Exome Sequencing Identifies Truncating Mutations in Human SERPINF1 in Autosomal-Recessive Osteogenesis Imperfecta. The American Journal of Human Genetics 88:3, 362-371
CrossRef20
Elena Makareeva, Nydea A. Aviles, Sergey Leikin. (2011) Chaperoning osteogenesis: new protein-folding disease paradigms. Trends in Cell Biology 21:3, 168-176
CrossRef21
Shawna M. Pyott, Melanie G. Pepin, Ulrike Schwarze, Kathleen Yang, Gretchen Smith, Peter H. Byers. (2011) Recurrence of perinatal lethal osteogenesis imperfecta in sibships: Parsing the risk between parental mosaicism for dominant mutations and autosomal recessive inheritance. Genetics in Medicine 13:2, 125-130
CrossRef22
Toshiyuki Fukada, Taiho Kambe. (2011) Molecular and genetic features of zinc transporters in physiology and pathogenesis. Metallomics 3:7, 662
CrossRef23
Toshiyuki Fukada, Yoshinobu Asada, Kenji Mishima, Shinji Shimoda, Ichiro Saito. (2011) Slc39a13/Zip13: A Crucial Zinc Transporter Involved in Tooth Development and Inherited Disorders. Journal of Oral Biosciences 53:1, 1-12
CrossRef24
V. Cormier-Daire. (2011) Cartografía genética de las enfermedades óseas constitucionales. EMC - Aparato Locomotor 44:2, 1-6
CrossRef25
Erica P. Homan, Frank Rauch, Ingo Grafe, Caressa Lietman, Jennifer A. Doll, Brian Dawson, Terry Bertin, Dobrawa Napierala, Roy Morello, Richard Gibbs, Lisa White, Rika Miki, Daniel H. Cohn, Susan Crawford, Rose Travers, Francis H. Glorieux, Brendan Lee. (2011) Mutations in SERPINF1 cause Osteogenesis imperfecta Type VI. Journal of Bone and Mineral Researchn/a-n/a
CrossRef26
Víctor Martínez-Glez, Maria Valencia, José A. Caparrós-Martín, Mona Aglan, Samia Temtamy, Jair Tenorio, Veronica Pulido, Uschi Lindert, Marianne Rohrbach, David Eyre, Cecilia Giunta, Pablo Lapunzina, Victor L. Ruiz-Perez. (2011) Identification of a mutation causing deficient BMP1/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta. Human Mutationn/a-n/a
CrossRef27
Nick Bishop. (2010) Characterising and treating osteogenesis imperfecta. Early Human Development 86:11, 743-746
CrossRef28
Bettina A Gentry, J. Andries Ferreira, Amanda J. McCambridge, Marybeth Brown, Charlotte L. Phillips. (2010) Skeletal muscle weakness in osteogeneis imperfecta mice. Matrix Biology 29:7, 638-644
CrossRef29
Fleur S. van Dijk, Margriet Huizer, Ariana Kariminejad, Carlo L. Marcelis, Astrid S. Plomp, Paulien A. Terhal, Hanne Meijers-Heijboer, Marjan M. Weiss, Rick R. van Rijn, Jan M. Cobben, Gerard Pals. (2010) Complete COL1A1 allele deletions in osteogenesis imperfecta. Genetics in Medicine1
CrossRef30
Pablo Lapunzina, Mona Aglan, Samia Temtamy, José A. Caparrós-Martín, Maria Valencia, Rocío Letón, Victor Martínez-Glez, Rasha Elhossini, Khalda Amr, Nuria Vilaboa, Victor L. Ruiz-Perez. (2010) Identification of a Frameshift Mutation in Osterix in a Patient with Recessive Osteogenesis Imperfecta. The American Journal of Human Genetics 87:1, 110-114
CrossRef31
G. H. Y. Li, A. W. C. Kung, Q.-Y. Huang. (2010) Common variants in FLNB/CRTAP, not ARHGEF3 at 3p, are associated with osteoporosis in southern Chinese women. Osteoporosis International 21:6, 1009-1020
CrossRef32
Roy Morello, Frank Rauch. (2010) Role of Cartilage-Associated Protein in Skeletal Development. Current Osteoporosis Reports 8:2, 77-83
CrossRef33
Kelly L. Gorres, Ronald T. Raines. (2010) Prolyl 4-hydroxylase. Critical Reviews in Biochemistry and Molecular Biology 45:2, 106-124
CrossRef34
Yasemin Alanay, Hrispima Avaygan, Natalia Camacho, G. Eda Utine, Koray Boduroglu, Dilek Aktas, Mehmet Alikasifoglu, Ergul Tuncbilek, Diclehan Orhan, Filiz Tiker Bakar, Bernard Zabel, Andrea Superti-Furga, Leena Bruckner-Tuderman, Cindy J.R. Curry, Shawna Pyott, Peter H. Byers, David R. Eyre, Dustin Baldridge, Brendan Lee, Amy E. Merrill, Elaine C. Davis, Daniel H. Cohn, Nurten Akarsu, Deborah Krakow. (2010) Mutations in the Gene Encoding the RER Protein FKBP65 Cause Autosomal-Recessive Osteogenesis Imperfecta. The American Journal of Human Genetics 86:4, 551-559
CrossRef35
Deborah Krakow, David L. Rimoin. (2010) The Skeletal Dysplasias. Genetics in Medicine1
CrossRef36
Helena E. Christiansen, Ulrike Schwarze, Shawna M. Pyott, Abdulrahman AlSwaid, Mohammed Al Balwi, Shatha Alrasheed, Melanie G. Pepin, Mary Ann Weis, David R. Eyre, Peter H. Byers. (2010) Homozygosity for a Missense Mutation in SERPINH1, which Encodes the Collagen Chaperone Protein HSP47, Results in Severe Recessive Osteogenesis Imperfecta. The American Journal of Human Genetics 86:3, 389-398
CrossRef37
N. Fratzl-Zelman, R. Morello, B. Lee, F. Rauch, F.H. Glorieux, B.M. Misof, K. Klaushofer, P. Roschger. (2010) CRTAP deficiency leads to abnormally high bone matrix mineralization in a murine model and in children with osteogenesis imperfecta type VII. Bone 46:3, 820-826
CrossRef38
Barnes, Aileen M., Carter, Erin M., Cabral, Wayne A., Weis, MaryAnn, Chang, Weizhong, Makareeva, Elena, Leikin, Sergey, Rotimi, Charles N., Eyre, David R., Raggio, Cathleen L., Marini, Joan C., . (2010) Lack of Cyclophilin B in Osteogenesis Imperfecta with Normal Collagen Folding. New England Journal of Medicine 362:6, 521-528
Full Text39
W. Chang, A. M. Barnes, W. A. Cabral, J. N. Bodurtha, J. C. Marini. (2010) Prolyl 3-hydroxylase 1 and CRTAP are mutually stabilizing in the endoplasmic reticulum collagen prolyl 3-hydroxylation complex. Human Molecular Genetics 19:2, 223-234
CrossRef40
Joan C. Marini, Wayne A. Cabral, Aileen M. Barnes. (2010) Null mutations in LEPRE1 and CRTAP cause severe recessive osteogenesis imperfecta. Cell and Tissue Research 339:1, 59-70
CrossRef41
F.S. Van Dijk, G. Pals, R.R. Van Rijn, P.G.J. Nikkels, J.M. Cobben. (2010) Classification of Osteogenesis Imperfecta revisited. European Journal of Medical Genetics 53:1, 1-5
CrossRef42
J SHAPIRO. 2010. Inherited and Related Disorders of Bone Matrix Synthesis in Men. , 505-522.
CrossRef43
Jay R Shapiro, Paul D Sponsellor. (2009) Osteogenesis imperfecta: questions and answers. Current Opinion in Pediatrics 21:6, 709-716
CrossRef44
Fleur S Van Dijk, Isabel M Nesbitt, Peter G J Nikkels, Ann Dalton, Ernie M H F Bongers, Jiddeke M van de Kamp, Yvonne Hilhorst-Hofstee, Nicolette S Den Hollander, Augusta M A Lachmeijer, Carlo L Marcelis, Gita M B Tan-Sindhunata, Rick R van Rijn, Hanne Meijers-Heijboer, Jan M Cobben, Gerard Pals. (2009) CRTAP mutations in lethal and severe osteogenesis imperfecta: the importance of combining biochemical and molecular genetic analysis. European Journal of Human Genetics 17:12, 1560-1569
CrossRef45
Ian M. Carr, Katarzyna Szymanska, Eamonn Sheridan, Alexander F. Markham, David T. Bonthron, Colin A. Johnson. (2009) Shadow autozygosity mapping by linkage exclusion (SAMPLE): a simple strategy to identify the genetic basis of lethal autosomal recessive disorders. Human Mutation 30:12, 1642-1649
CrossRef46
Ying-Xia Cui, Xin-Yi Xia, Yi-Chao Shi, Li Wei, Quan Liang, Bing Yao, Yi-Feng Ge, Yu-Feng Huang, Xiao-Jun Li. (2009) A G560S mutation in α1 (I) collagen causes familial osteogenesis imperfecta type IV. Clinica Chimica Acta 409:1-2, 145-146
CrossRef47
Fleur S. van Dijk, Isabel M. Nesbitt, Eline H. Zwikstra, Peter G.J. Nikkels, Sander R. Piersma, Silvina A. Fratantoni, Connie R. Jimenez, Margriet Huizer, Alice C. Morsman, Jan M. Cobben, Mirjam H.H. van Roij, Mariet W. Elting, Jonathan I.M.L. Verbeke, Liliane C.D. Wijnaendts, Nick J. Shaw, Wolfgang Högler, Carole McKeown, Erik A. Sistermans, Ann Dalton, Hanne Meijers-Heijboer, Gerard Pals. (2009) PPIB Mutations Cause Severe Osteogenesis Imperfecta. The American Journal of Human Genetics 85:4, 521-527
CrossRef48
Christopher Barnett, Jacob C. Langer, Aleksander Hinek, Timothy J. Bradley, David Chitayat. (2009) Looking past the lump: genetic aspects of inguinal hernia in children. Journal of Pediatric Surgery 44:7, 1423-1431
CrossRef49
Donald Basel, Robert D. Steiner. (2009) Osteogenesis imperfecta: Recent findings shed new light on this once well-understood condition. Genetics in Medicine 11:6, 375-385
CrossRef50
W. X. Tian, W. P. Zhang, J. K. Li, D. R. Bi, D. Z. Guo, S. Y. Pan, Y. H. Zhang, P. Qin. (2009) Identification of differentially expressed genes in the growth plate of broiler chickens with thiram-induced tibial dyschondroplasia. Avian Pathology 38:2, 161-166
CrossRef51
Moira S. Cheung, Francis H. Glorieux, Frank Rauch. (2009) Intravenous Pamidronate in Osteogenesis Imperfecta Type VII. Calcified Tissue International 84:3, 203-209
CrossRef52
Christopher Niyibizi, Feng Li. (2009) Potential implications of cell therapy for osteogenesis imperfecta. International Journal of Clinical Rheumatology 4:1, 57-66
CrossRef53
Dustin Baldridge, Ulrike Schwarze, Roy Morello, Jennifer Lennington, Terry K. Bertin, James M. Pace, Melanie G. Pepin, MaryAnn Weis, David R. Eyre, Jennifer Walsh, Deborah Lambert, Andrew Green, Haynes Robinson, Melonie Michelson, Gunnar Houge, Carl Lindman, Judith Martin, Jewell Ward, Emmanuelle Lemyre, John J. Mitchell, Deborah Krakow, David L. Rimoin, Daniel H. Cohn, Peter H. Byers, Brendan Lee. (2008) CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta. Human Mutation 29:12, 1435-1442
CrossRef54
D. L. Bodian, T.-F. Chan, A. Poon, U. Schwarze, K. Yang, P. H. Byers, P.-Y. Kwok, T. E. Klein. (2008) Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype-phenotype relationships. Human Molecular Genetics 18:3, 463-471
CrossRef55
Abimbola A. Obafemi, Dorothy I. Bulas, James Troendle, Joan C. Marini. (2008) Popcorn calcification in osteogenesis imperfecta: Incidence, progression, and molecular correlation. American Journal of Medical Genetics Part A 146A:21, 2725-2732
CrossRef56
Stephen M. Krane. (2008) The importance of proline residues in the structure, stability and susceptibility to proteolytic degradation of collagens. Amino Acids 35:4, 703-710
CrossRef57
Ting-Fung Chan, Annie Poon, Analabha Basu, Nick R. Addleman, Justin Chen, Angie Phong, Peter H. Byers, Teri E. Klein, Pui-Yan Kwok. (2008) Natural variation in four human collagen genes across an ethnically diverse population. Genomics 91:4, 307-314
CrossRef58
Dagistan Tolga Arioz, Gulengul Nadirgil Koken, Resit Koken, Kamil Cagri Kose, Arif Serhan Cevrioglu. (2008) Isolated intrauterine femoral fracture in an otherwise normal fetus. Journal of Obstetrics and Gynaecology Research 34:1, 92-94
CrossRef59
AM Lund, F Joensen, E Christensen, M Dunø, F Skovby, M Schwartz. (2008) A novel arginine-to-cysteine substitution in the triple helical region of the α1(I) collagen chain in a family with an osteogenesis imperfecta/Ehlers-Danlos phenotype. Clinical Genetics 73:1, 97-101
CrossRef60
ALLEN W. ROOT. 2008. Disorders of Bone Mineral Metabolism: Normal Homeostasis. , 74-126.
CrossRef61
ALLEN W. ROOT, FRANK B. DIAMOND. 2008. Disorders of Mineral Homeostasis in the Newborn, Infant, Child, and Adolescent. , 686-769.
CrossRef62
Guillermo E. Chacon, Carlos M. Ugalde, Marvin F. Jabero. (2007) Genetic Disorders and Bone Affecting the Craniofacial Skeleton. Oral and Maxillofacial Surgery Clinics of North America 19:4, 467-474
CrossRef63
Elizabeth Martin, Jay R. Shapiro. (2007) Osteogenesis imperfecta: Epidemiology and pathophysiology. Current Osteoporosis Reports 5:3, 91-97
CrossRef64
(2007) Brittle bones break wide open. Matrix Biology 26:4, 211-212
CrossRef65
Wayne A Cabral, Weizhong Chang, Aileen M Barnes, MaryAnn Weis, Melissa A Scott, Sergey Leikin, Elena Makareeva, Natalia V Kuznetsova, Kenneth N Rosenbaum, Cynthia J Tifft, Dorothy I Bulas, Chahira Kozma, Peter A Smith, David R Eyre, Joan C Marini. (2007) Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nature Genetics 39:3, 359-365
CrossRef66
S. Ferrari, E. Seeman, G. J. Strewler. (2007) Clinical and Basic Research Papers - December 2006 Selections. International Bone and Mineral Society Knowledge Environment 4:1, 1-6
CrossRef
